|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010744,
umls-concept:C0017337,
umls-concept:C0024530,
umls-concept:C0026882,
umls-concept:C0030498,
umls-concept:C0030705,
umls-concept:C0032150,
umls-concept:C0086898,
umls-concept:C0205421,
umls-concept:C0332281,
umls-concept:C0332293,
umls-concept:C0939219
|
|
pubmed:dateCreated |
2009-2-12
|
|
pubmed:abstractText |
Fixed-dose combination antimalarial drugs have played an increasingly important role in the treatment and chemoprophylaxis of falciparum malaria since the worldwide failure of monotherapy with chloroquine. Atovaquone-proguanil is one such combination drug used both for prophylaxis in travellers, and for treatment of acute malaria cases in European hospitals and clinics.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-10447880,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-10898682,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-12057021,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-12665429,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-12686039,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-15186499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-15478057,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-15827276,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-16962361,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-17020611,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19021900-8821609
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1475-2875
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
240
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19021900-Adult,
pubmed-meshheading:19021900-Animals,
pubmed-meshheading:19021900-Antimalarials,
pubmed-meshheading:19021900-Atovaquone,
pubmed-meshheading:19021900-Child, Preschool,
pubmed-meshheading:19021900-Cytochromes b,
pubmed-meshheading:19021900-DNA, Protozoan,
pubmed-meshheading:19021900-Drug Therapy, Combination,
pubmed-meshheading:19021900-Female,
pubmed-meshheading:19021900-Genotype,
pubmed-meshheading:19021900-Humans,
pubmed-meshheading:19021900-Malaria, Falciparum,
pubmed-meshheading:19021900-Male,
pubmed-meshheading:19021900-Middle Aged,
pubmed-meshheading:19021900-Mutation,
pubmed-meshheading:19021900-Parasitemia,
pubmed-meshheading:19021900-Plasmodium falciparum,
pubmed-meshheading:19021900-Polymerase Chain Reaction,
pubmed-meshheading:19021900-Proguanil,
pubmed-meshheading:19021900-Recurrence,
pubmed-meshheading:19021900-Time Factors,
pubmed-meshheading:19021900-Treatment Failure
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.
|
|
pubmed:affiliation |
Department of Clinical Parasitology, Hospital for Tropical Diseases, Mortimer Market, Capper St, London, WC1E 6AU, UK. colin.sutherland@lshtm.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
